Alphamab Oncology and Pathos reach international licensing agreement for TROP2/HER3 bispecific ADC.
On August 4, Alphamab Oncology (“Alphamab”) announced a licensing agreement with Pathos AI (“Pathos”) for its proprietary, “First-in-Class” TROP2/HER3 bispecific antibody-drug conjugate (ADC), JSKN016. Under the…